Ann: Voluntary Suspension, page-158

Management will actually be more than a year late from their original timeline.

The reason why is due to the scope of respiratory diseases being applied for simultaneously, number of hospitals included in the trial and volume of patients needed - but you wouldn't know this, as you haven't been following RAP from the early days.

ResApp have been valued comfortably at this 200M market cap level for the past year on zero revenue. The problem is the Motley Fools of the world just quite can't comprehend how this has been possible.

ResApp are just as much a business as they are a big data play, and there will be no alternative in the near future. A few contracts landed solely in the US with Telehealth providers and ResApp will be able to command a P/E of 30+ just like all other medical and biomed stocks which are unmatched in their field, you just have to look at the American markets to see how well they are priced. Except this time ResApp will also be trading cash flow positive.

Its amazing to see how many posters come out of the woodwork during these times, most remain quiet all year and provide little to no value in their posts. A lot of smoke blowing without understanding fundamentals, market size, let alone the Telehealth industry and the value proposition ResApp brings.

Next Wednesday we will see exceptional results, it only takes a few revisits to past presentations and announcements to see how bullish management are, and everyone will be jumping back in. The Motley Fools of the world will again have no idea why, and will write a few more negative pieces around $1, but the smart money by then will already holding RAP.